EGFR and neoplasm: Despite patient selection for anti‐EGFR MoAbs based on RAS mutations in the tumor, only 40–45% of patients with wild‐type mCRC have clinical benefits resulting in partial response in 8–13% and stable disease in 32% of patients (van Helden et al., 2017; Karapetis et al., 2008; Lievre et al., 2008; Van Cutsem et al., 2015).